Introduction Although many countries have introduced pictorial warning labels (PWLs), few use efficacy labels or inserts offering supportive cessation advice or outlining benefits of quitting. Theory ...

Objective Adoption of smoke-free policies (SFPs) in public venues, workplaces and other settings may prevent chronic smoking-related diseases, such as cardiovascular diseases (CVDs) and respiratory ...

Background Oral nicotine pouches (ONPs) have rapidly gained popularity in recent years. While ONPs likely expose users to fewer toxicants than cigarettes, they contain nicotine and may initiate, ...

Objective To estimate the impact of standardising the colour and branding of disposable vaping devices on young people’s interest in trying them. Design, setting and participants Data were from ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Introduction This study offers a comprehensive examination of the pricing strategies/dynamics used by the tobacco/nicotine industry in response to tax increases using Ukraine as a case study during ...

Background Tobacco taxation is the most effective strategy for reducing tobacco consumption, yet it remains underused globally, especially in low- and middle-income countries. This study aimed to ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Background Cigarette smoking is associated with adverse health outcomes in people with and without disabilities. However, little is known about disability prevalence among people who smoke. The ...

We discuss progress made with respect to reducing the burden of disease caused by tobacco use within the WHO European Region and outline major issues and challenges regarding ongoing implementation of ...

Correspondence to Dr Marzena Hiler, Center for Tobacco Products, Office of Science, US Food and Drug Administration, Silver Spring, Maryland, USA; Marzena.Hiler{at}fda.hhs.gov Objective This scoping ...